Arcturus Therapeutics Holdings Inc - ESG Rating & Company Profile powered by AI
This Sustainability score for Arcturus Therapeutics Holdings Inc represents the company's transparency towards the United Nations SDGs. The webpage contains a free Sustainability analysis for Arcturus Therapeutics Holdings Inc. This assessment of Arcturus Therapeutics Holdings Inc was assembled by All Street Sevva using proprietary machine learning.
Arcturus Therapeutics Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.3; made up of an environmental score of 6.0, social score of 4.8 and governance score of 8.0.
6.3
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
402 | United Laboratories International Holdings Ltd | 6.4 | High |
402 | Zenabis Global Inc | 6.4 | High |
427 | Arcturus Therapeutics Holdings Inc | 6.3 | High |
427 | Calliditas Therapeutics AB | 6.3 | High |
427 | Carna Biosciences Inc | 6.3 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Arcturus Therapeutics Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Does Arcturus Therapeutics Holdings Inc disclose current and historical energy intensity?
Does Arcturus Therapeutics Holdings Inc report the average age of the workforce?
Does Arcturus Therapeutics Holdings Inc reference operational or capital allocation in relation to climate change?
Does Arcturus Therapeutics Holdings Inc disclose its ethnicity pay gap?
Does Arcturus Therapeutics Holdings Inc disclose cybersecurity risks?
Does Arcturus Therapeutics Holdings Inc offer flexible work?
Does Arcturus Therapeutics Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Arcturus Therapeutics Holdings Inc disclose the number of employees in R&D functions?
Does Arcturus Therapeutics Holdings Inc conduct supply chain audits?
Does Arcturus Therapeutics Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Arcturus Therapeutics Holdings Inc conduct 360 degree staff reviews?
Does Arcturus Therapeutics Holdings Inc disclose the individual responsible for D&I?
Does Arcturus Therapeutics Holdings Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Arcturus Therapeutics Holdings Inc disclose current and / or historical scope 2 emissions?
Does Arcturus Therapeutics Holdings Inc disclose water use targets?
Does Arcturus Therapeutics Holdings Inc have careers partnerships with academic institutions?
Did Arcturus Therapeutics Holdings Inc have a product recall in the last two years?
Does Arcturus Therapeutics Holdings Inc disclose incidents of discrimination?
Does Arcturus Therapeutics Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Has Arcturus Therapeutics Holdings Inc issued a profit warning in the past 24 months?
Does Arcturus Therapeutics Holdings Inc disclose parental leave metrics?
Does Arcturus Therapeutics Holdings Inc disclose climate scenario or pathway analysis?
Does Arcturus Therapeutics Holdings Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Arcturus Therapeutics Holdings Inc disclose the pay ratio of women to men?
Does Arcturus Therapeutics Holdings Inc support suppliers with sustainability related research and development?
Does Arcturus Therapeutics Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Arcturus Therapeutics Holdings Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Arcturus Therapeutics Holdings Inc involved in embryonic stem cell research?
Does Arcturus Therapeutics Holdings Inc disclose GHG and Air Emissions intensity?
Does Arcturus Therapeutics Holdings Inc disclose its waste policy?
Does Arcturus Therapeutics Holdings Inc report according to TCFD requirements?
Does Arcturus Therapeutics Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Arcturus Therapeutics Holdings Inc disclose energy use targets?
Does Arcturus Therapeutics Holdings Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Arcturus Therapeutics Holdings Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Arcturus Therapeutics Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.